• Explore /
  • Poster
  • / Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

Abstract Video & Slides Poster

Authors

null

Brindley Sonal Hapuarachi

Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

Brindley Sonal Hapuarachi , Rebecca Lee , Adeel Khan , Laura Woodhouse , Valentinos Kounnis , Fiona Britton , Jessica Coyle , Kathleen Connors , Neethu Billy Graham Mariam , Jamie Weaver , Tom Waddell , Richard Hubner , Konstantinos Kamposioras , Wasat Mansoor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4039)

DOI

10.1200/JCO.2021.39.15_suppl.4039

Abstract #

4039

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Liyu Su

First Author: Rixci Ramirez

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.

Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.

First Author: Yuri Yoshinami

First Author: Mark R. Middleton